News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News


Pharmaceutical Technology Europe
Volume 23, Issue 12

News bites

EC probes J&J and Novartis

The European Commission has launched another antitrust investigation, this time examining whether contracts between Johnson & Johnson and Novartis were designed to delay the market entry of generic versions of Fentanyl in the Netherlands.

Read more at: http://www.PharmTech.com/ecprobe

GSK's US settlement

GlaxoSmithKline has come to a tentative agreement with the US government to conclude ongoing investigations relating to sales and marketing practices. The settlement is still subject to negotiation, but GSK expects to pay around $3 billion, which is covered by existing legal provisions.

Read more at: http://www.PharmTech.com/gsksettles

Lily–Amyline alliance ends

Eli Lilly and Amylin have terminated their alliance relating to the diabetes medication exenatide. Amylin will have responsibility for exanatide's global development and commercialisation while Eli Lilly will receive an upfront payment of $250 million and a secured note for $1.2 billion plus interest.

Read more at: http://www.PharmTech.com/lillyamylin

Annex 16 revisions

The EMA has released a concept paper for consultation that recommends a revision to Annex 16 of the Guide to Good Manufacturing of Medicinal Products. According to the EMA, the revision will address new falsified medicines legislation and the industry's complicated global supply chains.

Read more at: http://www.PharmTech.com/annex16


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here